Document is current
Any future updates will be listed below
-
Authors
Femiano, Cinzia
Bruno, Antonio
Gilio, Luana
Buttari, Fabio
Dolcetti, Ettore
Galifi, Giovanni
Azzolini, Federica
Borrelli, Angela
Furlan, Roberto
Finardi, Annamaria
Musella, Alessandra
Mandolesi, Georgia
Storto, Marianna
Centonze, Diego
Stampanoni Bassi, Mario
- License Information
-
More Information
Article History
Received: 31 January 2024
Accepted: 9 July 2024
First Online: 27 August 2024
Competing interests
: FB acted as advisory board members for Teva and Roche and received honoraria for speaking or consultation fees from Merck Serono, Teva, Biogen Idec, Sanofi, and Novartis, and non-financial support from Merck Serono, Teva, Biogen Idec, and Sanofi. DC is an Advisory Board member of Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, and Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen Idec, Celgene, Merck Serono, Novartis, Roche, Sanofi- Genzyme and Teva. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
